Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions

Planta Medica

Volumn 78, Issue 13, 2012, Pages 1458-1477

  Hermann, Robert ^a   Von Richter, Oliver ^b  

^a Clinical Research Appliance   (Germany)

^b Merck Serono GmbH   (Germany)

Author keywords

botanical drugs; complementary and alternative medicines; drug interactions; herbal drugs; pharmacokinetics

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIGOXIN; DONEPEZIL; ECHINACEA EXTRACT; GARLIC EXTRACT; GARLIPURE; GINKGO BILOBA EXTRACT; GINKGOLON 24; GINSENG EXTRACT; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; HERBACEOUS AGENT; HYDRASTIS CANADENSIS EXTRACT; LOSARTAN; METRONIDAZOLE; MIDAZOLAM; OMEPRAZOLE; PANAX QUINQUEFOLIUS EXTRACT; REMEMBER FX; RIFAMPICIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; TALINOLOL; TAVONIN; THISILYN; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

COGNITIVE DEFECT; DEMENTIA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HERB DRUG INTERACTION; HUMAN; INTERMITTENT CLAUDICATION; LOW DRUG DOSE; MEMORY DISORDER; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; ECHINACEA; GARLIC; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; HYDRASTIS; MILK THISTLE; P-GLYCOPROTEIN; PANAX; PHARMACOKINETICS; PLANT PREPARATIONS;

ALLIUM SATIVUM; GINKGO (GENUS); GINKGO BILOBA; HYDRASTIS CANADENSIS; PANAX GINSENG; SILYBUM MARIANUM;

EID: 84866070528     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1315117     Document Type: Review

References (112)

1. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med: 2004; 116 478 485
2. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med: 2005; 11 42 49
3. Singh SR, Levine MAH. Natural health product use in Canada: analysis of the National Population Health Survey. Can J Clin Pharmacol: 2006; 13 e240 e250
4. Singh SR, Levine MAH. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol: 2007; 47 249 258
5. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA: 2002; 287 337 344
6. European medicines Agency (EMA) Guideline on the Investigation of Drug Interactions. CPMP/EWP/560/95/Rev. 1 - Corr.; 22 April 2010. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 05/WC500090112.pdf Accessed June 06, 2012
7. Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylendioxyphenyl components. Drug Metab Dispos: 2003; 31 1391 1397
8. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther: 2005; 77 415 426
9. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tony Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther: 2008; 83 61 69
10. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol: 2012; 68 213 217
11. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs: 2009; 69 1777 1798
12. Johne A, Roots I. Clinical drug interactions with medicinal herbs. Evid Based Integr Med: 2005; 2 207 228
13. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab: 2008; 9 1063 1120
14. University of Washington Metabolism & Transport Drug Interaction Database (DIDB). Available at http://www.druginteractioninfo.org/ Accessed June 06, 2012
15. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets: 2000; 1 25 58
16. Kressmann S, Müller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol: 2002; 54 661 669
17. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther: 2002; 72 276 287
18. Gurley B, Gardner S, Hubbard M. Clinical assessment of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. Johns wort, garlic oil, Panax ginseng, and Ginkgo biloba. Drugs Aging: 2005; 22 525 539
19. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol: 2003; 23 576 581
20. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol: 2004; 44 538 542
21. Robertson SM, Davey RT, Voel J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin: 2008; 24 591 599
22. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol: 2005; 59 602 604
23. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull: 2004; 27 2006 2009
24. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol: 2006; 46 1290 1298
25. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol: 2010; 66 503 509
26. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2005; 59 425 432
27. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol: 2006; 46 214 221
28. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther: 2006; 13 24 31
29. Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics: 2004; 14 841 850
30. Lei HP, Wang G, Wang LS, Ou-yang DS, Chen H, Li Q, Zhang W, Tan ZR, Fan L, He YJ, Zhou HH. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother: 2009; 43 726 731
31. Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, Liu LJ, Zhou HH. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol: 2009; 68 201 206
32. Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther: 2003; 10 247 251
33. Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother: 2009; 43 944 949
34. Fan L, Mao XQ, Tao GY, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei HP, Hu DL, Huang YF, Wang D, Zhou HH. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica: 2009; 39 249 254
35. Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects-a double blind placebo-controlled, crossover study. Clin Nutr: 2006; 25 606 616
36. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos: 2007; 35 1956 1962
37. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther: 2009; 86 299 306
38. Lu WJ, Huang JD, Lai ML. The effects of ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol: 2006; 46 628 634
39. Kim BH, Kim KP, Lim KS, Kim JR, Yoon SH, Cho JY, Lee YO, Lee KH, Jang IJ, Shin SG, Yu KS. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther: 2010; 32 380 390
40. Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatté T, Fuhr U. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol: 2012; 68 553 560
41. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol: 2005; 59 602 604
42. Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon: 2011; 11 173
43. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res: 2006; 124 491 504
44. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther: 2010; 332 1081 1087
45. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med: 2007; 73 731 741
46. Sridar C, Goosen T, Kent U, Williams J. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos: 2004; 32 587 594
47. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos: 2000; 28 1270 1273
48. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol: 2007; 85 966 978
49. Leber HW, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung: 1976; 26 1603 1605
50. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther: 2004; 76 428 440
51. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol: 2006; 46 201 213
52. Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med: 2007; 73 1429 1435
53. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. Johns wort, and Echinacea. Mol Nutr Food Res: 2008; 52 755 763
54. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy: 2003; 23 866 870
55. Piscitelli S, Formentini E. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy: 2002; 22 551 556
56. Rao BN, Srinivas M, Kumar YS, Rao YM. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metab Drug Interact: 2007; 22 175 185
57. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res: 2005; 11 7800 7806
58. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung: 2004; 54 109 113
59. Han Y, Guo D, Chen YY, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol: 2009; 65 585 591
60. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Disp: 2006; 34 69 74
61. Han Y, Guo D, Chen Y, Tan ZR, Zhou HH. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica: 2009; 39 694 699
62. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA: 2000; 97 3473 3478
63. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res: 2009; 26 560 567
64. Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, Shin JG. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res: 2008; 25 1807 1814
65. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther: 2010; 87 130 133
66. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep: 2008; 12 1 23
67. Helms S. Cancer prevention and therapeutics: Panax ginseng. Alternat Med Rev: 2004; 9 259 274
68. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol: 1999; 58 1685 1693
69. An G, Morris ME. Herbal supplement-based interactions. In: Pang KS, Rodrigues AD, Peter RM. editors Enzyme- and transporter-based drug-drug interactions. New York Springer: 2010; 555 584
70. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol: 2003; 43 643 648
71. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos: 2003; 31 519 522
72. Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW, Dobs AS, Brown TT. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Alternat Med: 2008; 8 50
73. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS. Possible differential induction of phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol: 2008; 48 599 609
74. Jiang X, Blair EYL, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol: 2006; 46 1370 1378
75. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St Johns wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2004; 57 592 599
76. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarins effect in healthy patients. Ann Intern Med: 2004; 141 23 27
77. Weber HA, Zart MK, Hodges AE, Molloy HM, OBrien BM, Moody LA, Clark AP, Harris RK, Overstreet JD, Smith CS. Chemical comparison of goldenseal (Hydrastis canadensis L.) root powder from three commercial suppliers. J Agric Food Chem: 2003; 51 7352 7358
78. Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB. Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. Planta Med: 2011; 77 835 840
79. Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol: 2003; 43 1283 1288
80. Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, Jann MW. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol: 2002; 42 1165 1170
81. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (February 2012). Available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf Accessed June 06, 2012
82. Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos: 2007; 35 240 245
83. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol: 2005; 61 567 572
84. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol: 2006; 28 25 29
85. Breithaupt-Grögler K, Ling M, Boudoulas H, Belz GG. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. Circulation: 1997; 96 2649 2655
86. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens: 1994; 12 463 468
87. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal - Part I. Prog Drug Res: 2001; 56 1 76
88. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. Significance of garlic and its constituents in cancer and cardiovascular disease in vitro interactions of water-soluble garlic components with human. J Nutr: 2006; 136 806 809
89. Lam YWF, Ernst E. Botanical products - drug interactions: focus on garlic, ginkgo and ginseng. In: Lam YWF, Huang SM, Hall SD. editors Herbal supplements - drug interactions, Volume 162. London Taylor & Francis, Inc.: 2006; 107 121
90. Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos: 2007; 35 995 1000
91. Fukao T, Hosono T, Misawa S, Seki T, Ariga T. The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride. Food Chem Toxicol: 2004; 42 743 749
92. Markowitz JS, Lindsay DeVane C, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther: 2003; 74 170 177
93. Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol: 2001; 20 321 327
94. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Res: 1994; 3 155 160
95. Jacek H, Rentsch KM, Steinert HC, Pauli-Magnus C, Meier PJ, Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test. Clin Pharmacol Ther: 2004; 75 P80
96. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol: 2003; 55 199 202
97. Lunn DJ, Aarons L. The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J Pharmacokinet Biopharm: 1998; 26 47 74
98. Gisolf EH, van Heeswijk RP, Hoetelmans RW, Danner SA. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS: 2000; 14 801 805
99. Blumenthal M. The complete German commission E monographs, therapeutic guide to herbal medicines. Austin American Botanical Council: 1998
100. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther: 2004; 75 89 100
101. Moltó J, Valle M, Miranda C, Cedeno S, Negredo E, Barbanoj MJ, Clotet B. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother: 2011; 55 326 330
102. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy: 2010; 30 797 805
103. Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, Matthias A, Lehmann RP, McLachlan AJ. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol: 2010; 69 508 515
104. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med: 2003; 3 221 230
105. Gurley B, Swain A, Williams D. Gauging the clinical significance of Pglycoproteinmediated herbdrug interactions: comparative effects of St. Johns wort, Echinacea, clarithromycin, and rifampin on dogoxin pharmacokinetics. Mol Nutr Food Res: 2008; 52 772 779
106. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit: 2005; 27 549 557
107. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktailo" approach. Clin Pharmacol Ther: 2007; 81 270 283
108. Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist: 2006; 11 742 752
109. Lee LS, Andrade AS, Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis: 2006; 43 1052 1059
110. Nowack R, Andrassy J, Fischereder M, Unger M. Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients. Clin Pharmacol Therap: 2009; 85 439 443
111. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol: 2004; 22 2489 2503
112. Gore-Felton C, Vosvick M, Power R, Koopman C, Ashton E, Bachmann MH, Israelski D, Spiegel D. Alternative therapies: a common practice among men and women living with HIV. J Assoc Nurses AIDS Care: 2003; 14 17 27